Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects

Table 4

Clinical laboratory data in the high- and low-dose groups.

	First week of DKT administration		-value	Second week of DKT administration		value	Third week of DKT administration		value
	Low-dose group	High-dose group		Low-dose group	High-dose group		Low-dose group	High-dose group
Na (mEq/L)	139 (137–140)	139 (137–141)	0.938	139 (133–141)	137 (134–142)	0.792	136 (132–137)	138 (137–139)	0.291
K (mEq/L)	4.3 (4.0–4.5)	4.5 (3.9–4.9)	0.615	4.3 (3.8–4.6)	4.6 (4.3–4.8)	0.269	4.7 (4.2–4.9)	4.6 (4–5.5)	1
Cl (mEq/L)	103 (98–105)	101 (100–105)	0.938	103 (99–105)	104 (102–105)	0.792	100 (98–102)	102 (96–105)	0.786
AST (IU/L)	23 (18–35)	17 (15–21)	0.153	24 (19–34)	17 (15–23)	0.131	21 (20–25)	15 (14–18)	0.0668
ALT (IU/L)	21 (13–27)	13 (11–21)	0.315	17 (13–26)	16 (10–18)	0.487	12 (12–18)	12 (12–18)	1
T-Bil (mg/dL)	0.6 (0.4–0.8)	0.5 (0.4–0.5)	0.326	0.5 (0.4–0.5)	0.4 (0.3–0.5)	0.283	0.6 (0.6–0.6)	0.7 (0.5–0.8)	1
BUN (mg/dL)	21 (13–24)	11 (10–14)	0.142	17 (15–26)	18 (14–24)	0.779	12 (10–13)	18 (12–26)	0.25
Cre (mg/dL)	0.7 (0.6–1.0)	0.8 (0.6–0.9)	0.91	0.6 (0.5–0.7)	0.7 (0.6–0.9)	0.461	0.5 (0.4–0.6)	0.7 (0.6–0.9)	0.393
Alb (g/dL)	3.2 (2.5–3.3)	3.3 (3.0–4.0)	0.443	3.0 (2.6–3.4)	4 (3.8–4.2)	0.0317	3.0 (3.0–3.2)	3.8 (3.8–4.4)	0.0722
BS (mg/dL)	108 (101–121)	99 (98–114)	0.69	133 (125–140)	106 (99–111)	0.2	89 (89-89)	100 (97–102)	0.667

AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-Bil, total bilirubin; Cre, serum creatinine; BUN, blood urea nitrogen; Alb, albumin; BS, blood sugar; DKT, Daikenchuto.